Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation for Solid Cancer

Biology of Blood and Marrow Transplantation

Volumn 22, Issue 4, 2016, Pages 676-681

  Omazic, Brigitta ^a   Remberger, Mats ^a   Barkholt, Lisbeth ^a   Söderdahl, Gunnar ^a   Potácová, Zuzana ^a   Wersäll, Peter ^a   Ericzon, Bo Göran ^a   Mattsson, Jonas ^a   Ringdén, Olle ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Cholangiocarcinoma; Colon carcinoma; Pancreatic adenocarcinoma; Renal carcinoma

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; METHOTREXATE; MYCOPHENOLATE MOFETIL; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY; FLUDARABINE; MYELOABLATIVE AGENT; VIDARABINE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BACTEREMIA; BILE DUCT CARCINOMA; BREAST CANCER; CANCER MORTALITY; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; COLON CARCINOMA; CYTOMEGALOVIRUS INFECTION; DISEASE CLASSIFICATION; DONOR LYMPHOCYTE INFUSION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; GRAFT FAILURE; HLA SYSTEM; HOSPITALIZATION; HUMAN; KIDNEY CARCINOMA; LIVER TRANSPLANTATION; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; NONMYELOABLATIVE CONDITIONING; PANCREAS ADENOCARCINOMA; PROSTATE CANCER; RISK FACTOR; SYSTEMIC MYCOSIS; THROMBOCYTE TRANSFUSION; TUMOR ENGRAFTMENT; ADENOCARCINOMA; ALLOTRANSPLANTATION; ANALOGS AND DERIVATIVES; BILE DUCT NEOPLASMS; BREAST NEOPLASMS; COLONIC NEOPLASMS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; KIDNEY NEOPLASMS; METASTASIS; MIDDLE AGED; MORTALITY; PANCREATIC NEOPLASMS; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING;

ADENOCARCINOMA; ADULT; AGED; BILE DUCT NEOPLASMS; BREAST NEOPLASMS; COLONIC NEOPLASMS; CYCLOPHOSPHAMIDE; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 84960517177     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.12.017     Document Type: Article

References (31)

1. Weiden P.L., Sullivan K.M., Flournoy N., et al. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981, 304:1529-1533.
2. Ringden O., Karlsson H., Olsson R., et al. The allogeneic graft-versus-cancer effect. Br J Haematol 2009, 147:614-633.
3. Marmont A.M., Horowitz M.M., Gale R.P., et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991, 78:2120-2130.
4. Ben-Yosef R., Or R., Nagler A., Slavin S. Graft-versus-tumour and graft-versus-leukaemia effect in patient with concurrent breast cancer and acute myelocytic leukaemia. Lancet 1996, 348:1242-1243.
5. Childs R., Chernoff A., Contentin N., et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000, 343:750-758.
6. Barkholt L., Bregni M., Remberger M., et al. Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Ann Oncol 2006, 17:1134-1140.
7. Blaise D., Bay J.O., Faucher C., et al. Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood 2004, 103:435-441.
8. Bregni M., Dodero A., Peccatori J., et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 2002, 99:4234-4236.
9. Childs R., Srinivasan R. Advances in allogeneic stem cell transplantation: directing graft-versus-leukemia at solid tumors. Cancer J 2002, 8:2-11.
10. Aglietta M., Barkholt L., Schianca F.C., et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation in metastatic colorectal cancer as a novel adoptive cell therapy approach. The European group for blood and marrow transplantation experience. Biol Blood Marrow Transplant 2009, 15:326-335.
11. Bay J.O., Fleury J., Choufi B., et al. Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients. Bone Marrow Transplant 2002, 30:95-102.
12. Hentschke P., Barkholt L., Uzunel M., et al. Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant 2003, 31:253-261.
13. Kanda Y., Omuro Y., Baba E., et al. Allo-SCT using reduced-intensity conditioning against advanced pancreatic cancer: a Japanese survey. Bone Marrow Transplant 2008, 42:99-103.
14. Soderdahl G., Barkholt L., Hentschke P., et al. Liver transplantation followed by adjuvant nonmyeloablative hemopoietic stem cell transplantation for advanced primary liver cancer in humans. Transplantation 2003, 75:1061-1066.
15. Pirker R., Pereira J.R., Szczesna A., et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009, 373:1525-1531.
16. Thompson Coon J.S., Liu Z., Hoyle M., et al. Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness. Br J Cancer 2009, 101:238-243.
17. Ringden O., Soderdahl G., Mattsson J., et al. Transplantation of autologous and allogeneic bone marrow with liver from a cadaveric donor for primary liver cancer. Transplantation 2000, 69:2043-2048.
18. Ringden O., Remberger M., Runde V., et al. Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation. Blood 1999, 94:455-464.
19. McSweeney P.A., Niederwieser D., Shizuru J.A., et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001, 97:3390-3400.
20. Le Blanc K., Remberger M., Uzunel M., et al. A comparison of nonmyeloablative and reduced-intensity conditioning for allogeneic stem-cell transplantation. Transplantation 2004, 78:1014-1020.
21. Childs R.W., Clave E., Tisdale J., et al. Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect. J Clin Oncol 1999, 17:2044-2049.
22. Ringden O., Remberger M., Persson U., et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 1995, 15:619-625.
23. Remberger M., Svahn B.M., Mattsson J., Ringden O. Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation 2004, 78:122-127.
24. Ringden O., Erkers T., Nava S., et al. Fetal membrane cells for treatment of steroid-refractory acute graft-versus-host disease. Stem Cells 2013, 31:592-601.
25. Svahn B.M., Remberger M., Myrback K.E., et al. Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care. Blood 2002, 100:4317-4324.
26. Kolb H.J., Mittermuller J., Clemm C., et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990, 76:2462-2465.
27. Mattsson J., Uzunel M., Remberger M., et al. Minimal residual disease is common after allogeneic stem cell transplantation in patients with B cell chronic lymphocytic leukemia and may be controlled by graft-versus-host disease. Leukemia 2000, 14:247-254.
28. Barkholt L., Danielsson R., Calissendorff B., et al. Indium-111-labelled donor-lymphocyte infusion by way of hepatic artery and radio-frequency ablation against liver metastases of renal and colon carcinoma after allogeneic hematopoietic stem-cell transplantation. Transplantation 2004, 78:697-703.
29. Thomas E.D., Buckner C.D., Banaji M., et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 1977, 49:511-533.
30. Ringden O., Uzunel M., Rasmusson I., et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006, 81:1390-1397.
31. Rubio M.T., Kim Y.M., Sachs T., et al. Antitumor effect of donor marrow graft rejection induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: critical role for recipient-derived IFN-gamma. Blood 2003, 102:2300-2307.